FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Warns Aurobindo Pharmas Eugia Unit

FDA has issued a warning letter to a Telangana, India, sterile drug manufacturing facility operated by Aurobindo Pharma subsidiary Eugia Pharma Specia...

latest-news-card-1
Biologics

Capricor Plans Deramiocel BLA Amendment After FDA Input

Capricor Therapeutics plans to amend its BLA for deramiocel to modify its proposed indication after discussions with FDA produced a potential path tow...

latest-news-card-1
Human Drugs

Accelerated Approval for Zenbexus Combo in Multiple Myeloma

FDA grants Bristol-Myers Squibb accelerated approval for Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethason...

Human Drugs

3 Observations on Reliance Life Sciences FDA-483

FDA releases the Form FDA-483 issued following an inspection at Indias Reliance Life Sciences drug manufacturing facility in Navi Mumbai.

latest-news-card-1
Human Drugs

PDUFA VIII Commitment Letter Outlines Changes to Drug Review, Manufacturing Oversight

FDA releases the proposed recommendations for the eighth reauthorization of the Prescription Drug User Fee Act, outlining changes to drug review, manu...

latest-news-card-1
Human Drugs

Guidance on Risk-Based Approach to Drug Packaging Systems

FDA issues a draft guidance proposing a risk-based framework for evaluating the container-closure systems used to package human drugs and biologics.

latest-news-card-1
Human Drugs

Experts Warn of Edema Risk With Vykat XR as FDA Evaluates Risk

Foundation for Prader-Willi Research warns that real-world reports of edema and other serious heart and respiratory problems among patients taking Neu...

Medical Devices

FDA Seeks Injunction Against Steiner Biotechnology

The Department of Justice seeks an injunction to stop Steiner Biotechnology from manufacturing and marketing adulterated and misbranded dental medical...

Human Drugs

FDA Questions Zynlontas Benefit/Risk: Report

FDA is raising questions about the risk/benefit of ADC Therapeutics Zynlonta as a second-line treatment for diffuse large B-cell lymphoma.

latest-news-card-1
Human Drugs

Use More Advisory Committee Temporary Voting Members: Column

A Center for Medicine in the Public Interest opinion column calls on FDA to more aggressively recruit and use advisory committee temporary voting memb...